...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation.
【24h】

Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation.

机译:用噬菌体对补体的凝集素途径的选择性抑制展示了针对甘露糖结合的凝集素相关丝氨酸蛋白酶(MASP)-1和-2的选定肽:MASP-1对凝集素途径活化的重要贡献。

获取原文
获取原文并翻译 | 示例
           

摘要

The complement system, an essential part of the innate immune system, can be activated through three distinct routes: the classical, the alternative, and the lectin pathways. The contribution of individual activation pathways to different biological processes can be assessed by using pathway-selective inhibitors. In this paper, we report lectin pathway-specific short peptide inhibitors developed by phage display against mannose-binding lectin-associated serine proteases (MASPs), MASP-1 and MASP-2. On the basis of the selected peptide sequences, two 14-mer peptides, designated as sunflower MASP inhibitor (SFMI)-1 and SFMI-2, were produced and characterized. SFMI-1 inhibits both MASP-1 and MASP-2 with a K(I) of 65 and 1030 nM, respectively, whereas SFMI-2 inhibits only MASP-2 with a K(I) of 180 nM. Both peptides block the lectin pathway activation completely while leaving the classical and the alternative routes intact and fully functional, demonstrating that of all complement proteases only MASP-1 and/or MASP-2 are inhibited by these peptides. In a C4 deposition inhibitor assay using preactivated MASP-2, SFMI-2 is 10-fold more effective than SFMI-1 in accordance with the fact that SFMI-2 is a more potent inhibitor of MASP-2. Surprisingly, however, out of the two peptides, SFMI-1 is much more effective in preventing C3 and C4 deposition when normal human serum containing zymogen MASPs is used. This suggests that MASP-1 has a crucial role in the initiation steps of lectin pathway activation most probably by activating MASP-2. Because the lectin pathway has been implicated in several life-threatening pathological states, these inhibitors should be considered as lead compounds toward developing lectin pathway blocking therapeutics.
机译:补体系统是先天免疫系统的重要组成部分,可以通过三种不同的途径激活:经典途径,替代途径和凝集素途径。可以通过使用途径选择性抑制剂来评估单个激活途径对不同生物学过程的贡献。在本文中,我们报告了针对噬菌体展示针对甘露糖结合凝集素相关丝氨酸蛋白酶(MASPs),MASP-1和MASP-2开发的凝集素途径特异性短肽抑制剂。根据所选的肽序列,产生并表征了两个14聚体肽,分别称为向日葵MASP抑制剂(SFMI)-1和SFMI-2。 SFMI-1抑制MASP-1和MASP-2的K(I)分别为65和1030 nM,而SFMI-2仅抑制MASP-2的K(I)为180 nM。两种肽都完全阻断凝集素途径的激活,同时保留了经典途径和替代途径的完整和完全功能,这表明所有补体蛋白酶中只有MASP-1和/或MASP-2被这些肽抑制。在使用预活化的MASP-2的C4沉积抑制剂测定中,根据SFMI-2是MASP-2的更有效抑制剂的事实,SFMI-2比SFMI-1的效力高10倍。但是,令人惊讶的是,当使用正常的含酶原MASP的人血清时,在这两种肽中,SFMI-1在预防C3和C4沉积方面要有效得多。这表明,MASP-1最有可能通过激活MASP-2在凝集素途径激活的起始步骤中发挥关键作用。由于凝集素途径已牵涉到几种威胁生命的病理状态,因此应将这些抑制剂视为导致发展凝集素途径阻断疗法的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号